Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia

APLAR Journal of Rheumatology

Volumn 9, Issue 1, 2006, Pages 24-36

  Lau, Edith M C ^a   Sambrook, P ^b   Seeman, E ^c   Leong, K H ^d   Leung, P C ^e   Delmas, P ^f  

^a Hong Kong Orthopaedic and Osteoporosis Center for Treatment and Research   (Hong Kong)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d GLENEAGLES HOSPITAL   (Singapore)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f UNIVERSITÉ LYON 1   (France)

Author keywords

Bisphosphonates; Dual X ray densitometry; Osteoporosis; SERM; Strontium ranleate

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CORTICOSTEROID; ERGOCALCIFEROL; ESTROGEN; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; IPRIFLAVONE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PHYTOESTROGEN; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TESTOSTERONE; VITAMIN D; VITAMIN D DERIVATIVE;

ARTICLE; ASIA; BONE DENSITY; CLINICAL TRIAL; COMMUNITY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAGILITY FRACTURE; HUMAN; LOW DRUG DOSE; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

EID: 33746564602     PISSN: 02190494     EISSN: 14798077     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2006.00161.x     Document Type: Article

References (98)

1. Lau EMC, Lee JK, Suriwongpaisal P, et al. (2001) The incidence of hip fracture in four Asian countries: The Asian Osteoporosis Study (AOS). Osteoporos Int 12, 239-43.
2. Ho SC, Bacon WE, Harris T, Lorker A, Maggi S (1993) Hip fracture rates in Hong Kong and the United States, 1988 through 1989. Am J Public Health 83, 694-7.
3. Lau EMC, Cooper C, Wickham C, Donnan S, Barker DJP (1990) Hip fracture in Hong Kong and Britain. Int J Epidemiol 19, 1119-21.
4. Cooper C, Campion G, Melton LJ (1992) Hip fractures in the elderly: A world-wide projection. Osteoporos Int 2, 285-9.
5. Gullberg B, Johnell O, Kanis JA (1997) World wide projection for hip fracture. Osteoporos Int 7, 407-13.
6. Lau EMC, Chan HHL, Woo J, et al. (1996) Normal ranges for vertebral height ratios and prevalence of vertebral fracture in Hong Kong Chinese: a comparison with American Caucasians. J Bone Miner Res 11, 1364-8.
7. Black DM, Cummings SR, Stone K, Hudes E, Palermo L, Steiger P (1991) A new approach to defining normal vertebral dimension. J Bone Miner Res 6, 883-92.
8. Xu L, Cummings SR, Mingwei Q, et al. (2000) Vertebral fractures in Beijing, China: The Beijing Osteoporosis Project. J Bone Miner Res 15, 2019-25.
9. Tsai KS, Twu Sj, Chieng Pu, et al. (1996) Prevalence of vertebral fractures in Chinese men and women in urban Taiwanese communities. Calcif Tissue Int 59, 249-53.
10. Kanis JA, Melton L III, Christiansen C, Johnston CC Jr, Khaltaev N (1994). The diagnosis of osteoporosis. J Bone Miner Res 8, 1137-41.
11. Black DM, Cummings SR, Melton LJ III (1992) Appendicular bone mineral density and a woman's lifetime risk of hip fracture. J Bone Miner Res 7, 639-46.
12. Lau EMC, Woo J, Leung PC, Leung D (1993) Low bone mineral density, grip strength and skin-fold thickness are important risk factors for hip fracture in Hong Kong Chinese. Osteoporos Int 3, 66-70.
13. Eddy D, Johnston C, Cummings SR, et al. (1998) Osteoporosis: Review of evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 8, S7-S80.
14. Koh LH, Sedrine WB, Torralba TP, et al. (2001) A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporosis Int 12, 699-705.
15. Hannon R, Blumsohn A, Naylor K, Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability. J Bone Miner Res 13, 1124-33.
16. Greenspan SL, Parker RA, Ferguson L, et al. (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial. J Bone Miner Res 13, 1431-8.
17. Garnero P, Hausherr E, Chapuy M-C, et al. (1996) Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res 11, 1531-8.
18. Seeman E, Eisman JA (2004) Treatment of osteoporosis: Why, whom, when and how to treat. MJA 180, 298-303.
19. Black DM, Cummings SR, Karpf D, et al. (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348, 1535-41.
20. Cummings SR (1996) Treatable and untreatable risk factors for hip fracture. Bone 18 (Suppl 3), 165S-167S.
21. Harris ST, Watts NB, Genant HK, et al. (1999) Effects of risedroante treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 282, 1344-52.
22. Reginster JY, Minne HW, Sorensosen OH, et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11, 83-91.
23. McClung MR, Geusens P, Miller PD, et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344, 333-40.
24. Lau EMC, Woo J, Chan YH, Griffith J (2000) Alendronate prevents bone loss in Chinese women with osteoporosis. Bone 27, 677-80.
25. Rosen CJ, Hochberg MC, Bonnick SL, et.al. (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res 20, 141-51.
26. Dufresne TE, Chmielewski PA, Manhart TD, et.al. (2003) Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 73, 423-32.
27. Chesnut CH, Ettinger MP, Miller PD, et.al. (2005) Ibandronate produces significant, similar antifracture efficacy in North American and European women: New clinical findings from BONE. Curr Med Res Opin 21, 391-401.
28. Delmas PD, Recker RR, Chesnut CH III, et.al. (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study. Osteoporos Int 15, 792-8.
29. Delmas PD, Bjarnason BH, Mitlak NH, et al. (1997) Effect of raloxifene on bone mineral density, serum cholesterol and uterine endometrium in postmenopausal women. N Engl J Med 337, 1641-7.
30. Delmas PD, Ensrud KE, Adachi JD, et al. (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocr Metab 87, 3609-17.
31. Ettinger B, Black DM, Mitlak BH, et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3 year randomized controlled trial. JAMA 282, 637-45.
32. Kanis JA, Johnell O, Black DM, et al. (2003) Effect of raloxifene on the risk of new vertbral fracture in postmenopausal women with osteopenia or osteoporosis: A reanalysis of the multiple outcomes of raloxifene evaluation trial. Bone 33, 293-300.
33. Cauley JA, Norton L, Loppman ME, et al. (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4 year results from the MORE trial. Breast Cancer Res Treat 65, 125-34.
34. Kung AW, Chao HT, Huang KE, et al. (2003) Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women. J Clin Endocrinaol Metab 88, 3130-6.
35. Ettinger B, Genant HK, Cann CE (1985) Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 102, 319-24.
36. Writing Group for the PEPI trial. (1996) Effects of hormone therapy on bone mineral density. JAMA 276, 1389-96.
37. Cauley JA, Robbins J, Chen Z, et al. (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: The women's health initiative randomized trial. JAMA 290, 1729-38.
38. Writing Group for Women's Health Initiative Investigators. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288, 321-33.
39. Neer RM, Arnaud CD, Zanchetta JR, et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344, 1434-41.
40. Lindsay R, Scheele WH, Neer R, et al. (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatied in postmenopausal women with osteoporosis. Arch Intern Med 164, 2024-30.
41. Meunier PJ, Roux C, Seeman E, et al. (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Engl J Med 350, 459-68.
42. Alexandersen P, Toussaint A, Christiansen C, et al. (2001) Ipriflavone in the treatment of postmenopausal osteoporosis: A randomized controlled trial. JAMA 285, 1482-8.
43. Alekel DL, Germain AS, Peterson Ct, et al. (2000) Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 72, 844-52.
44. Potter SM, Baum JA, Teng H, et al. (1998) Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 68 (6 Suppl), 1375S-1379S.
45. Chesnut CH, Silverman S, Andriano K, et al. (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. Am J Med 109, 267-76.
46. Lyritis GP, Tsakalakos N, Magiasis B, et al. (1991) Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: A double blind placebo controlled clinical study. Calcif Tissue Int 49, 369-72.
47. Pun KK, Chan MB (1989) Analgesic effect of intranasal salmon calcitonin in the treatment of osteoprotic vertebral fractures. Clin Ther 11, 205-9.
48. Dawson-Hughes B, Harris S, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337, 670-6.
49. Chapuy MC, Arlot ME, Duboeuf F, et al. (1993) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327, 1637-42.
50. Orimo H, Shiraki M, Hayashi T, Nakamura T (1987) Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3. Bone Mineral 3, 47-52.
51. Gorai I, Chaki O, Taguchi Y, et al. (1999) Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3. Calcified Tissue Int 65, 16-22.
52. Gallagher JC, Fowler SE, Detter JR, Sherman SS (2001) Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 86, 3618-28.
53. Tilyard MW, Spears GF, Thomas J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326, 357-62.
54. Institute of Medicine (1997) Dietary Reference Intakes for Calcium, Phosphorous, Magnesium, Vitamin D, and Fluoride. The National Academics Press, Washington DC.
55. Lau E, Woo J, Lam V, Hong A (2001) Milk supplementation of the diet of postmenopausal Chinese women on a low calcium intake retards bone loss. J Bone Miner Res 16, 1704-9.
56. Reid IR, Ames RW, Evans MC, et al. (1993) Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 328, 460-4.
57. Nordin BEC (1997) Calcium and osteoporosis. Nutrition 13, 664-86.
58. Chevalley T, Rizzoli R, Nydegger V, et al. (1994) Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin D replete elderly patients. Osteoporos Int 4, 245-52.
59. Recker RR, Hinders S, Davies KM, et al. (1996) Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 11, 1961-6.
60. Orwoll E, Ettinger M, Weiss S, et al. (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343, 604-10.
61. Ringe JD, Faber H, Dorst A (2001) Alendronate treatment of established primary osteoporosis in men: Results of a 2-year prospective study. J Clin Endocrinol Metab 86, 5252-5.
62. Devogelaer JP, De Cooman S, Nagant de Deuxchaisnes C (1992) Low bone mass in hypogonadal males: Effect of testosterone substitution therapy, a densitometric study. Mauritas 15, 17-23.
63. Katznelson L, Finklestein JS, Schoenfeld DA, et.al. (1996) Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81, 4358-65.
64. Francis RM (1999) The effects of testosterone on osteoporosis in men. Clin Endocrinol 50, 411-4.
65. Snyder PJ, Peachey H, Hannoush P, et.al. (1999) Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84, 2647-53.
66. Leifke E, Korner HC, Link TM, et.al. (1998) Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle strength in hypogonadal men. Eur J Endocrinol 138, 51-8.
67. van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis. Osteoporosis Int 13, 777-87.
68. Guidelines Working Group for Bone and Tooth Society, National Osteoporosis Society and Royal College of Physician, London. (2002) Glucocorticoid-induced osteoporosis. Guidelines for prevention and treatment 2002. Royal College of Physicians, London, UK.
69. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis. (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44, 496-1503.
70. Compson J (2004) US and UK guidelines for glucocorticoid-induced osteoporosis. similarities and differences. Curr Rheumatol Rep 6, 66-9.
71. Saag KG, Emkey R, Schnitzer TJ, et al. (1998) Alendronate for the treatment and prevention of glucocorticoid-induced osteoporosis. N Engl J Med 339, 292-9.
72. Reid DM, Hughes RA, Laan RF, et al. (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. J Bone Miner Res 15, 1006-20.
73. Adachi JD, Bensen WG, Brown J, et al. (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337, 382-7.
74. Cohen S, Levy RM, Keller M, et al. (1999) Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-Group study. Arthritis Rheum 42, 2309-18.
75. Roux C, Oriente P, Laan R, et al. (1998) Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 83, 1128-33.
76. Adachi JD, Saag KG, Delmas PD, et al. (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44, 202-11.
77. Wallach S, Cohen S, Reid DM, et al. (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67, 277-85.
78. Sambrook PN, Birmingham J, Kelly PJ, et al. (1993) Prevention of corticosteroid osteoporosis: A comparison of calcium, calcitriol and calcitonin. N Engl J Med 328, 1747-52.
79. Adachi J, Bensen W, Bianchi F, et al. (1996) Vitamin D and calcium in the prevention of corticosteroid-induced osteoporosis: A three year follow up study. J Rheumatol 23, 995-1000.
80. Reginster JY, Kuntz D, Verdicht W, et al. (1999) Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 9, 75-81.
81. Buckley LM, Leib ES, Cartularo KS, et al. (1996) Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 125, 961-8.
82. National Osteoporosis Foundation. (2003) Health professional's guide to rehabilitation of the patient with osteoporosis.
83. Lee YL, Yip MH (1996) The Osteoporotic Spine. Clin Orth 323, 91-7.
84. Myers ER, Wilson SE (1997) Biomechanics of osteoporosis and vertebral fracture. Spine 22 (24 Suppl), 25S-31S.
85. Keller TS, Harrison De, Colloca CJ (2003) Prediction of osteoporotic spinal deformity. Spine 28, 455-62.
86. Lee RYW (2002) Measurement of movement of the lumbar spine. Physiotherapy Theory Prac 18, 159-64.
87. Cook DJ, Guyatt GH, Adachi JD (1993) Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum 36, 750-6.
88. McKay H, Petit MA, Schutz RW, et.al. (2000) Augmented trochanteric bone mineral density after modified physical education classes: A randomized school-based exercise intervention study in prepubescent and early pubescent children. J Pediatr 136, 156-62.
89. Snow-Harter C, Bouxsein ML, Lewis BT, et.al. (1992) Effects of resistance and endurance exercise on bone mineral status of young women: a randomized exercise intervention trial. J Bone Miner Res 7, 761-9.
90. Lohman T, Going S, Pamenter R, et.al. (1995) Effects of resistance training on regional and total bone mineral density in premenopausal women: A randomized prospective study. J Bone Miner Res 10, 1015-24.
91. Wolff I, Croonenborg J, Kemper H, et.al. (1999) The effect of exercise training programs on bone mass: A meta-analysis of published controlled trials in pre- and postmenopausal women. Osteoporos Int 9, 1-12.
92. Prince RL, Smith M, Dick IM, et.al. (1991) Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 325, 1189-95.
93. Felson DT, Zhang Y, Hannan MT, et.al. (1995) Alcohol intake and bone mineral density in elderly men and women. The Framingham Study. Am J Epidemiol 142, 485-92.
94. Holbrook TL, Barrett-Connor E (1993) A prospective study of alcohol consumption and bone mineral density. Br J Med 306, 1506-9.
95. Naves Diaz M, O'Neill TW, Silman AJ (1997) The influence of alcohol consumption on the risk of vertebral deformity. European Vertebral Osteoporosis Study Group. Osteoporos Int 7, 65-71.
96. Felson DT, Kiel DP, Anderson JJ, Kannel WB (1998) Alcohol consumption and hip fractures. The Framingham Study. Am J Epidemiol 128, 1102-10.
97. Tinetti ME, et al. (1994) A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 331, 821-7.
98. Parker MJ, Gillespie WJ, Gillespie LD (2005) Hip protectors for preventing hip fractures in older people. (A Cochrane review). Cochrane library: Issue 4.